Follicular Lymphoma
📧 Sign up to get email alerts when something new happens for Follicular Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma [Phase 1, Phase 2]
This document reports an ongoing Phase 1/2 study evaluating tazemetostat with rituximab and abbreviated bendamustine as frontline therapy fo…
-
EMA approval · 2026-02-16EMA Authorised: Lunsumio (mosunetuzumab) — Roche Registration GmbH
The EMA authorised Lunsumio (mosunetuzumab) for follicular lymphoma with conditional approval and orphan medicine designation granted to Roc…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. [Phase 1]
A Phase 1 clinical trial evaluating oral LP-168 in relapsed or refractory B-cell malignancies is recruiting. Target conditions include CLL/S…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Study of SGR-1505 in Mature B-Cell Neoplasms [Phase 1]
Schrödinger's SGR-1505 is being evaluated in a Phase 1 trial across multiple mature B-cell neoplasms and is currently recruiting. The study …
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies [Phase 1]
Phase 1 clinical trial from Mayo Clinic is evaluating BAFFR-based CAR-T cells with lymphodepletion (fludarabine and cyclophosphamide) for re…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS other · 2026-02-11Clinical Trial Update: Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
An Emory University-sponsored clinical trial is recruiting to evaluate human immune responses to vaccination in patients with lymphoma. The …
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma [Phase 1]
Phase 1 clinical trial assessing the safety of LTZ-301 in patients with various forms of non-Hodgkin lymphoma, currently recruiting.
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas [Phase 2]
A Phase 2 clinical trial evaluating the combination of acalabrutinib and obinutuzumab as initial therapy for previously untreated follicular…
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma [Phase 3]
Phase 3 trial to compare odronextamab plus chemotherapy versus rituximab plus chemotherapy in adults with follicular lymphoma to assess safe…
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas [Phase 2]
This Phase 2 clinical trial update describes evaluating rituximab in combination with zanubrutinib for indolent B-cell lymphomas, including …
-
CLINICAL_TRIALS research · 2026-02-04Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma [Phase 3]
Phase 3 study comparing mosunetuzumab plus lenalidomide to rituximab plus lenalidomide in relapsed or refractory follicular lymphoma, includ…
-
CLINICAL_TRIALS research · 2026-02-03Clinical Trial Update: Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP).
This clinical trial update notes that mosunetuzumab is being evaluated in a compassionate-use program for relapsed/refractory follicular lym…
-
CLINICAL_TRIALS trial_result · 2026-02-02Clinical Trial Update: Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma [Phase 1]
An early-phase study evaluating the combination of parsaclisib with standard therapy in newly diagnosed, high-risk diffuse large B-cell lymp…
-
CLINICAL_TRIALS trial_result · 2026-02-02Clinical Trial Update: Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell
An observational study of people living with HIV treated with CD19-directed CAR T-cell therapy has completed.
-
CLINICAL_TRIALS research · 2026-01-30Clinical Trial Update: A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A clinical trial update describes EO2463, a novel vaccine, being studied as monotherapy and in combination for indolent non-Hodgkin lymphoma…
-
CLINICAL_TRIALS withdrawal · 2026-01-30Clinical Trial Update: A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation [Phase 2]
Phase 2 trial of oral tazemetostat for relapsed/refractory follicular lymphoma without EZH2 gain-of-function mutation has been withdrawn.
-
CLINICAL_TRIALS research · 2026-01-30Clinical Trial Update: Evaluate the Safety and Clinical Activity of HH2853 [Phase 1, Phase 2]
The trial update indicates HH2853 is being studied in Phase 1/Phase 2 across follicular lymphoma, epithelioid sarcoma, peripheral T-cell lym…
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy [Phase 2]
A Phase 2 trial is evaluating whether vaccination with Prevnar 13 before and after CAR-T therapy can enhance cellular and humoral immunity i…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients [Phase 2]
A Phase 2 clinical trial evaluating the combination of mosunetuzumab and zanubrutinib in relapsed/refractory follicular lymphoma, currently …
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Clinical trial registry update for the RUBIN platform extension focusing on hematologic malignancies. It is currently recruiting for conditi…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy [Phase 3]
Phase 3 clinical trial evaluating a digital health intervention for self-management and telemonitoring in CAR-T therapy is currently recruit…
-
CLINICAL_TRIALS research · 2026-01-27Clinical Trial Update: IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma [Phase 3]
Phase 3 trial evaluating IMM0306 in combination with lenalidomide versus placebo in combination with lenalidomide for relapsed/refractory fo…
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: Efficacy and Safety of TC011 in Relapsed or Refractory Follicular Lymphoma [Phase 2]
Phase 2 clinical trial update on TC011 for relapsed or refractory follicular lymphoma, noting the study status as not yet recruiting and rep…
-
CLINICAL_TRIALS trial_result · 2026-01-21Clinical Trial Update: Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma [Phase 2]
A Phase 2 trial evaluating epcoritamab in combination with tazemetostat for relapsed or refractory follicular lymphoma (Grades I-IIIa) is cu…
-
CLINICAL_TRIALS research · 2026-01-21Clinical Trial Update: Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma [Phase 2]
Phase 2 clinical trial update evaluating Relmacabtagene autoleucel in combination with sintilimab for relapsed/refractory B-cell lymphomas; …